Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions
Related Party Transactions	11. Related Party Transactions As described in Note 8 above, the Company entered into the 2018 Lilly Agreement with Lilly in April 2018. During the three and six months ended June 30, 2022 and 2021, the Company recognized $2.9 million, $6.0 million, $2.7 million and $5.6 million, respectively, of related party revenue associated with Lilly collaboration agreements. As of June 30, 2022 and December 31, 2021, the Company had deferred revenue related to the collaboration agreements with Lilly of $16.3 million and $22.4 million, respectively. As of June 30, 2022 and December 31, 2021, the Company had less than $0.1 million of outstanding receivables with Lilly. In January 2021, the Company entered into a shared space arrangement with a portfolio company of Flagship Pioneering, one of the Company’s significant stockholders, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the shared space arrangement commenced in January 2021 and the initial term ended on December 31, 2021. Under this agreement, the Company recorded other income, net, of less than $0.1 million during the three months ended March 31, 2021 and the Company received cash payments of less than $0.1 million during the three months ended March 31, 2021. On February 1, 2022, the Company entered into a shared space arrangement with a portfolio company of Flagship Pioneering, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the shared space arrangement commenced on February 1, 2022 and continues for an initial term ending on July 31, 2023. The agreement may be renewed for six successive one-month periods. The Company will be paid a fee based on the portfolio company’s occupancy of the office and laboratory space. Under this agreement, the Company recorded other income, net, of less than $0.1 million during the three and six months ended June 30, 2022. The Company received $1.4 million of cash payments during the three and six months ended June 30, 2022, and as of June 30, 2022, the Company had less than $0.1 million of outstanding receivables under these agreements that were recorded within other current assets.

Related Party Transactions

6 Months Ended

Jun. 30, 2022

11. Related Party Transactions

As described in Note 8 above, the Company entered into the 2018 Lilly Agreement with Lilly in April 2018. During the three and six months ended June 30, 2022 and 2021, the Company recognized $2.9 million, $6.0 million, $2.7 million and $5.6 million, respectively, of related party revenue associated with Lilly collaboration agreements. As of June 30, 2022 and December 31, 2021, the Company had deferred revenue related to the collaboration agreements with Lilly of $16.3 million and $22.4 million, respectively. As of June 30, 2022 and December 31, 2021, the Company had less than $0.1 million of outstanding receivables with Lilly.

In January 2021, the Company entered into a shared space arrangement with a portfolio company of Flagship Pioneering, one of the Company’s significant stockholders, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the shared space arrangement commenced in January 2021 and the initial term ended on December 31, 2021. Under this agreement, the Company recorded other income, net, of less than $0.1 million during the three months ended March 31, 2021 and the Company received cash payments of less than $0.1 million during the three months ended March 31, 2021.

On February 1, 2022, the Company entered into a shared space arrangement with a portfolio company of Flagship Pioneering, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the shared space arrangement commenced on February 1, 2022 and continues for an initial term ending on July 31, 2023. The agreement may be renewed for six successive one-month periods. The Company will be paid a fee based on the portfolio company’s occupancy of the office and laboratory space. Under this agreement, the Company recorded other income, net, of less than $0.1 million during the three and six months ended June 30, 2022. The Company received $1.4 million of cash

payments during the three and six months ended June 30, 2022, and as of June 30, 2022, the Company had less than $0.1 million of outstanding receivables under these agreements that were recorded within other current assets.